News

Sharikas hired to attract Life Science companies to Greater Richmond

The Greater Richmond Partnership (“GRP”) has hired Kiryako Sharikas to join the team as Business Development Manager – Life Sciences. Sharikas will focus on targeting life science and pharmaceutical companies interested in expanding to the Richmond Region.

“Kiryako’s experience in marketing will translate well as he markets the region as the #1 mid-sized location in the U.S. for life science companies to invest,” said Jennifer Wakefield, President + CEO of the Greater Richmond Partnership. “With Kiryako on the team, GRP will now have a dedicated point of contact to expand the shared effort to make our region the capital of advanced pharmaceutical manufacturing.”

Sharikas has more than eight years of experience in digital marketing for employers including CoStar Group, Sheltering Arms, Compare.com and NetSearch. Sharikas’ experience will be a major asset as he transitions to the new role. Sharikas is a graduate of Virginia Commonwealth University and Reynolds Community College.

 

Read more here.

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and